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Abstract
Background: RNA-binding motif protein 3 (RBM3), involved in cell survival, has paradoxically been linked to both
oncogenesis as well as an increased survival in several cancers, including urothelial carcinoma (UCA).
Methods: The putative prognostic role of RBM3 was studied using cystectomy specimens with 152 invasive UCA with 35
matched metastases, 65 carcinomas in situ (CIS), 22 high-grade papillary UCAs (PAP), and 112 benign urothelium cases.
Results: The H-score (HS, staining intensity × % of positive cells) was used for RBM3 immunoexpression. CIS showed the
highest HS (mean = 140) followed by benign urothelium (mean = 97). Metastases showed higher HS than primary
invasive UCA (P≤ 0.0001), and high HS was associated with a lower pT stage (P≤ 0.0001) and a trend toward the
absence of lymphovascular invasion (LVI, P = 0.09), but not pN stage (P = 0.35) and surgical margin status (P = 0.81).
Univariate analysis (UVA) of disease recurrence only showed an association between pN stage and LVI (P = 0.005 and 0.03,
respectively). On UVA of mortality, pT stage was strongly associated with death (P = 0.01) while pN stage, LVI, surgical
margin status, and HS were not. Multivariate analysis confirmed the lack of HS association with recurrence (P = 0.08) and
death (P = 0.32).
Conclusions: Stronger RBM3 immunoexpression correlated with lower stage tumors and a diminished risk for LVI.
However, RBM3 does not seem to carry a prognostic significance for clinical outcome (recurrence and mortality).
The exact prognostic role of RBM3 in UCA is yet to be determined.
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Background
Single-strand RNA-binding proteins (RBPs) are in-
volved in RNA metabolism and in the regulation of the
genes’ transcription [1, 2] that are essential for cell sur-
vival under adverse growth conditions such as hypoxia
[3–5] and hypothermia [3]. Among these, one of the
“cold-shock” proteins [6] RNA-binding motif protein 3
(RBM3), which is expressed in many fetal and adult
tissues [7], has been shown to be induced during
hypothermia conditions [3, 8–10] to possibly limit the
decrease of protein synthesis [4, 11] and increase cell
survival.
The role of RBM3 in cancer has not yet been clarified.
A number of studies have suggested that RBM3 has
proto-oncogenic potential as its expression was found to
be up-regulated in various human tumors [3, 4]. It has
been shown to increase messenger RNA (mRNA) stabil-
ity and translation and to prevent apoptosis during cell
mitosis (a mitotic catastrophe) [12], and to also be in-
volved in p53-linked DNA damage repair [13]. Further-
more, RBM3 was found to be up-regulated in poorly
differentiated prostate cancers in comparison to normal
prostatic glands [14], as well as in low-grade vs high-
grade astrocytomas [15]. A strong association has been
found between RBM3 overexpression and early bio-
chemical prostate cancer recurrence in a large series
[16]. Interestingly, in a separate study [17], metastatic
prostate cancer samples showed significantly decreased
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mRBM3 levels. Down-regulation of cold-inducible pro-
teins including RBM3 in prostate cancer cells by expos-
ure to hyperthermia enhanced cancer cell response to
chemotherapy [13]. However, conflicting results emerged
from many clinical studies which have found high RBM3
expression to be associated with a better prognosis in
various cancers including colorectal cancer [18], melan-
oma [19, 20], estrogen-positive breast cancers [21] as
well as esophageal and gastric adenocarcinomas [22].
Recently, increased RBM3 nuclear expression was also
linked to cisplatin sensitivity and to an improvement
in the prognosis in epithelial ovarian cancers [23, 24],
as well as to a prolonged time to disease progression
in prostate cancer [25]. Finally, decreased expression
of RBM3 was associated with clinically more aggres-
sive urothelial bladder cancers [26] and treatment fail-
ure in metastatic testicular non-seminomatous germ
cell tumors [27].
The present study analyzes the putative prognostic
role of RBM3 in a large cohort of patients with urothe-
lial carcinoma (UCA) of the bladder by analyzing RBM3
immunohistochemical expression in various benign




Eight tissue microarrays (TMAs) were constructed by
using cystectomy tissues obtained from the surgical
pathology archives of the McGill University Health
Centre (Montreal, Quebec, Canada). Institutional ethical
guidelines regarding experimentation involving human
tissues were followed. Collectively, the samples repre-
sented 112 benign (101 normal urothelium cases and 11
normal prostate cases) and 274 malignant urothelial le-
sions (65 carcinoma in situ (CIS) cases, 22 high-grade
papillary urothelial lesions, 152 invasive, and 35 meta-
static lesions) obtained from cystectomy specimens col-
lected between 2000 and 2012. Each case was
represented by two separate 1-mm representative cores.
Using the American Joint Committee on Cancer (AJCC),
51 primary tumors (35 %) were classified as pT1 or pT2
and 95 primary tumors (65 %) were classified as pT3 or
pT4. Thirty-five cases were primary invasive and
matched metastatic tumors from the same patient.
Among invasive cases, 96 (64 %) specimens were classi-
fied as pN0 and 51 (34 %) as pN1/N2/N3; 5 cases were
designated as pNx in the original pathology report.
Sixty-three (41 %) cases showed lymphovascular invasion
(LVI) while 90 (59 %) did not. Clinical follow-up was
available in 106 patients with a mean duration of 2 years
follow-up. Twenty-two percent of patients recurred
while 17 % died of the disease.
Immunohistochemistry
Immunohistochemistry was performed by using a
Ventana automated system and Ventana iVIEW DAB
detection kit (Ventana Medical Systems, Inc, Tucson,
Arizona) at the immunohistochemistry laboratory of
McGill University Health Centre. Mouse antihuman
monoclonal RBM3 antibody AMAb90655 (Atlas Anti-
bodies, Stockholm, Sweden) was used. Nuclear stain-
ing intensity was evaluated semi-quantitatively by two
independent evaluators (LF and FB) as follows: 0 =
negative, 1 = weak staining, 2 = moderate staining, and
3 = intense staining. The few discrepancies that
existed between the two evaluators were discussed,
and a consensus was reached. For each core, the per-
centages of stained tumor cells of each intensity were
estimated. The H-score, defined as the sum of the
product of the percentage of tumor cells showing
RBM3 labeling (0–100) multiplied by the labeling
intensity (0–3), was calculated. For statistical pur-
poses, the H-score results of sample duplicates were
averaged in order to obtain a single value.
Statistical analysis
The data for continuous variable is expressed as
means (SD). Student’s t test or Mann-Whitney test
was used, as appropriate, to determine differences in
continuous variables. Categorical variables are pre-
sented as percentage. Pearson’s chi-square test or
Fisher’s exact test, as appropriate, was used to deter-
mine the differences in categorical variables. Both
univariate and multivariate logistic regression analyses
were performed to determine the association of
RBM3 expression and various pathological parameters
with recurrence and survival. From the univariate
analysis, variables with P < 0.05 and those which were
already established as significant were included in the
multivariate logistic regression analysis. P values <0.05
were considered statistically significant. All analyses
were performed using the SAS version 9.1.3 Service
Pack 4 statistical (Windows platform).
Results
RBM3 in different histological stages of UCA
Among the non-invasive lesions, CIS showed the highest
H-score (HS) (mean = 140 ± 107, P = 0.004), followed by
benign urothelium (mean = 97 ± 69) and papillary carcin-
oma (PAP) (mean = 64 ± 71). The mean HS was 51 ± 59
for invasive lesions and 95 ± 87 for metastases. For
matched cases, the HS was significantly higher in metas-
tases (mean = 96 ± 87) than in invasive samples (mean =
26 ± 87) (P ≤ 0.0001) (Fig. 1). Detailed results are
provided in Table 1.
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RBM3 in relation to pathological stages of UCA
Of the cystectomy pathological parameters, RBM3 over-
expression was significantly associated with a lower pT
stage (P ≤ 0.0001) even though a significant proportion
of these samples did not show a predominantly high-
intensity RBM3 staining (P = 0.003). No association was
found between RBM3 expression and pN stage (P = 0.35)
nor with the surgical margin status (P = 0.81). RBM3
overexpression showed a trend toward the absence of
lymphovascular invasion (P = 0.09).
Fig. 1 RBM3 immunoexpression and H&E morphology in benign urothelium (a), urothelial carcinoma in situ (b), primary invasive urothelial
carcinoma (c), and matched metastatic urothelial carcinoma (d)
Table 1 RBM3 immunoexpression in different urothelial lesions





(mean)0 1 2 3
Benign urothelium 112 8 (7 %) 21 (19 %) 24 (22 %) 58 (52 %) 2.2 61.1 97.3
Malignant urothelium 274
CIS 65 4 (6 %) 12 (18 %) 15 (23 %) 34 (52 %) 2.2 62.5 140.7
PAP 22 5 (23 %) 5 (23 %) 4 (18 %) 8 (36 %) 1.7 37.9 64.0
Invasive 152 39 (25 %) 28 (18 %) 34 (22 %) 52 (34 %) 1.6 40.2 40.2
Primary (matched) 35 14 (40 %) 14 (40 %) 3 (9 %) 4 (11 %) 0.9 29.3 26.1
Metastasis (matched) 35 6 (17 %) 5 (14 %) 6 (17 %) 18 (51 %) 2.0 50.9 95.6
CIS carcinoma in situ, PAP papillary carcinoma
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Recurrence analysis
On univariate analysis, pN stage and lymphovascular in-
vasion were strongly associated with recurrence (P =
0.005 and 0.03, respectively). In comparison, pT stage
showed a trend toward significant association (P = 0.1)
while the HS and surgical margins status showed no as-
sociation (P = 0.49 and 0.97, respectively). Multivariate
analysis (MVA) confirmed the lack of association be-
tween the HS and recurrence (P = 0.08) but failed to
confirm the association of recurrence to pN stage (P =
0.69) and to LVI (P = 0.08).
Mortality analysis
On univariate analysis, pT stage was strongly associated
with death of urologic cause (P = 0.01), while pN stage
(P = 0.17), lymphovascular invasion (P = 0.28), surgical
margin status (P = 0.18), and HS were not (P = 0.5). The
lack of association between the HS and death was
maintained using a MVA model (P = 0.32).
Discussion
This study examines the immunohistochemical expres-
sion of RBM3 in various benign and malignant urothelial
tissues. The RBM3 HS was highest in CIS lesions, and it
was also increased in metastases when compared to in-
vasive lesions. A high HS was also associated with a
lower pT stage and trended toward showing the absence
of LVI. RBM3 expression was not associated with pN
stage, nor with recurrence or death on both univariate
and multivariate analyses.
The literature concerning the exact role of RBM3 in
carcinogenesis has so far been conflicting. RBM3 is a
hypothermia-induced protein [3, 8–10] that has been
found to assist in mRNA stability [12] and to increase
translation efficiency in conditions of mild hypothermia
[8, 12]. In turn, these events minimize DNA damage and
reduce apoptotic events [12]. RBM3 mRNA and protein
expression are up-regulated in hypoxia in a hypoxia-
inducible factor 1 (HIF-1) independent manner [5] and
increase cellular protein synthesis in conditions of cellu-
lar starvation [4]. Down-regulation of RBM3 mRNA and
protein by small-interfering RNA (siRNA) reduces cell
proliferation and viability in human embryonic kidney
cells [4]. Thus, RBM3 appears to increase cell survival
and proliferation, particularly in specific adverse growth
conditions, and appears to be driving oncogenesis in vari-
ous cancers. In many studies, tumor cells from various tis-
sues including the colon, breast, pancreas, lung, ovary,
and prostate displayed a higher percentage of RBM3-
positive cells by immunohistochemistry as well as by RT-
PCR and Western blotting in comparison to their benign
counterparts [4, 12], with different studies reporting vari-
ous magnitudes of expression up-regulation (from 2.4-fold
[14] to 10-fold [12]). Furthermore, RBM3 was reported to
be associated with tumors’ grades as poorly differentiated
prostate tumors [14] and high-grade astrocytomas [15]
showed higher mRNA and immunoexpression of RBM3
when compared to well-differentiated and low-grade
tumors. In addition, an increased vulnerability of cells to
chemotherapy was noted after down-regulation of RBM3
in prostate cancer [13]. Concurrent with this portion of
the literature, our results in urothelial tissues show that
the immunohistochemical HS for RBM3 was 1.4-fold
higher in CIS compared to benign tissues and that in
matched cases, as well as significantly higher in metastases
in comparison to invasive primary samples. These results
indeed seem to suggest that RBM3 is in some way in-
volved in oncogenesis, although the fact that CIS lesions
show the highest HS of all the urothelial lesions analyzed,
including invasive and metastatic lesions, is somewhat
paradoxical. It is possible that CIS lesions with a high
RBM3 might be more aggressive and become invasive in a
shorter time frame for example; however, the testing of
this hypothesis would require matched cases of chrono-
logically evolutive lesions—benign, CIS, invasive urothelial
carcinoma, and eventually metastasis—which could not be
achieved in the current study. Previously, it has been ar-
gued that even though in vitro findings suggest RBM3 to
be a proto-oncogene, those results would not contradict
the fact that high expression of RBM3 in ovarian tumors
is associated with a favorable patient outcome since this
data would not have taken patient treatment into account
[23]. Other studies that associate high RBM3 expression
with a good prognosis in colon [18], breast [21], and
urothelial [26] cancer purposely highlighted the in vitro
data by Sureban et al. showing proto-oncogenic RBM3
properties [12]. To explain this seeming contradiction,
some rely on the argument that the majority of other clin-
ical studies on RBM3 and other proteins of the RBM fam-
ily associate them with good prognosis [21, 26], while one
study made efforts to validate the antibodies they used by
epitope mapping [18].
The reviewed literature (Table 2) shows that the
methods for Immunohistochemistry (IHC) evaluation of
RBM3 expression in TMAs are variable and inconsistent
among studies which could explain the conflicting results.
Several studies [20, 21, 23–26] combined the nuclear
RBM3-stained fraction with the intensity of the stain to
obtain a semi-quantitative value. The nuclear fraction is
usually defined into four categories, with the 1 and 2 % de-
fining the uppermost value of the “0” category and the
lowermost value of the “1” category, respectively. The dis-
tinction between these very narrow values can be difficult
and may lead to a positive bias, whereby perhaps biologic-
ally insignificant or potential artifactual staining of rare
cells can upgrade the sample from a negative to a positive
classification. Similarly, the nuclear intensity was scored
variably, with some authors using four categories
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Table 2 Summary of the literature: RBM3 studies in human cancers
Author, year (ref no.) Tumor type Overall results (may include
methods additional to IHC)
IHC quantification method Data adjustment for analysis
Jonsson et al., 2011 [2] Melanoma RBM3 is down-regulated in metastatic
melanoma, and high nuclear RBM3
expression in the primary tumor is an
independent marker of a prolonged OS.
Qualitative: when present, RBM3 was
expressed in >75 % of the cells, so
only the intensity of the staining
was scored (0–3).
Samples with scores 0, 1, and 2 pooled
together and compared to samples
with score 3.
Ehlen et al., 2010 [3] Ovarian cancer RBM3 expression is associated with cisplatin
sensitivity in vitro and with a good prognosis.
Semi-quantitative (combined nuclear score):
4 scores for nuclear fraction (0–1 %, 2–25 %,
26–75 %, and >75 %) and 3 scores for nuclear
staining intensity (negative, intermediate,
and moderate-strong).
None.
Jonsson et al., 2011 [4] Prostate cancer High RBM3 nuclear expression in prostate
cancer is associated with a prolonged
time to disease progression.
Semi-quantitative (combined nuclear score):
4 scores for nuclear fraction (0–1 %, 2–25 %,
26–75 %, and >75 %) and 4 scores for nuclear
staining intensity (negative, intermediate,
moderate, and strong).
RBM3 nuclear score was dichotomized into
weak vs strong using classification and
regression tree analysis (survival analyses).
Jogi et al., 2009 [5] Breast cancer Increased nuclear expression of RBM3 was
associated with a prolonged overall and
recurrence-free survival.
Semi-quantitative (combined nuclear score):
4 scores for nuclear fraction (0–1 %, 2–25 %,
26–75 %, and >75 %) and 4 scores for nuclear
staining intensity (negative, intermediate,
moderate, and strong).
RBM3 nuclear score was dichotomized
into <75 vs >75 % positive nuclear
staining (calculated optimal cutoff).
Nodin et al., 2012 [6] Melanoma RBM3 expression is an independent prognostic
factor for melanoma-specific survival but not
disease-free survival in the multivariable model.
Semi-quantitative (combined nuclear score):
4 scores for nuclear fraction (0–1 %, 2–25 %,
26–75 %, and >75 %) and 4 scores for nuclear
staining intensity (negative, intermediate,
moderate, and strong).
RBM3 nuclear score was dichotomized
into low vs high.
Ehlen et al., 2011 [7] Ovarian cancer Association between RBM3 expression and
several cellular processes involved in the
maintenance of DNA integrity.
Semi-quantitative (combined nuclear score):
4 scores for nuclear fraction (0–1 %, 2–25 %,
26–75 %, and >75 %) and 3 scores for nuclear
staining intensity (negative, intermediate,
and moderate-strong).
RBM3 nuclear score was dichotomized
into low vs high.
Boman et al., 2013 [18] Urothelial bladder cancer Loss of RBM3 expression is associated with
clinically more aggressive tumors and an
independent factor of poor prognosis.
Semi-quantitative (combined nuclear score):
4 scores for nuclear fraction (0–1 %, 2–25 %,
26–75 %, and >75 %) and 4 scores for nuclear
staining intensity (negative, intermediate,
moderate, and strong).
RBM3 nuclear score was trichotomized into
negative, intermediate, and high (survival
analyses) and dichotomized into negative
vs positive or negative-intermediate vs
high (relative risk of progression or
death from disease analyses).
Zhang et al., 2013 [20] Astrocytoma RBM3 overexpression may serve as an
important molecular mechanism underlying
astrocytic carcinogenesis and may have
proliferative and/or proto-oncogenic functions.
Qualitative only: negative, weakly positive,
moderately positive, and strongly positive.
None.
Grupp et al., 2014 [22] Prostate cancer High RBM3 expression is an independent
poor prognostic marker in prostate cancer.
Qualitative: scores combining the staining
intensity and the fraction of positive tumor














Table 2 Summary of the literature: RBM3 studies in human cancers (Continued)
Jonsson et al., 2014 [23] Esophageal and gastric
adenocarcinomas
High expression of RBM3 independently
predicts a reduced risk of recurrence and death.
Semi-quantitative (combined nuclear score):
4 scores for nuclear fraction (0–1 %, 2–25 %,
26–75 %, and >75 %) and 3 scores for nuclear
staining intensity (negative, intermediate,
and moderate-strong).
None for the comparison of RBM3
expression in various benign, malignant,
and metastatic tissues. RBM3 nuclear
score was dichotomized into low and
high (survival analyses).
Olofsson et al., 2015 [24] Testicular non-seminomatous
germ cell tumors (NSGCT)
Low RBM3 expression is an independent
predictor of treatment failure in
metastatic NSGCT.
Semi-quantitative (combined nuclear score):
4 scores for nuclear fraction (0–1 %, 2–25 %,
26–75 %, and >75 %) and 3 scores for nuclear
staining intensity (negative, intermediate,
and moderate-strong).
RBM3 nuclear score was dichotomized into
weak vs strong using classification and













(negative, weak, intermediate, strong) [20, 21, 25, 26]
while others pooling the intermediate and strong [23, 24]
or even the negative, weak, and intermediate categories
together [19]. Some on the other hand evaluated staining
intensity only, as long as a predominant portion of cells
displayed some staining [15, 19]. Also frequent is the di-
chotomization of RBM3 semi-quantitative data into low
and high categories for the purpose of survival analyses
[20, 21, 24–26], often based on seemingly random or un-
specified values. One single study used a regression tree
analysis to separate the data [25]. In the only previous
study analyzing RBM3 immunoexpression in UCA, the
data was dichotomized for survival analyses and trichoto-
mized for the analyses of clinicopathological parameters.
The current study uses a similar method of combined nu-
clear fraction and intensity to quantitatively analyze RBM3
expression in TMA samples. However, the calculated
values are used as such and the data therefore remains
quantitative, as opposed to the quantitative dichotomized
data described in the studies above. This method may
therefore be more precise when correlating RBM3 expres-
sion to clinicopathological parameters and survival, and
might also explain discrepancies related to mortality and
recurrence in studies examining RBM3 expression in the
colon and rectum [18], epithelial ovarian carcinoma [23],
and the breast [21], which found RBM3 expression to be
associated with longer overall survival and disease-free
survival.
Specifically concerning urothelial bladder cancer, the
only study currently published on this topic reported loss
of RBM3 expression to be associated with clinically more
aggressive tumors and to be an independent factor of poor
prognosis [26]. Using a large cohort of urothelial tumors,
Boman et al. used the combined nuclear score to examine
RBM3 IHC semi-quantitatively and reported reduced pa-
tient survival with decreasing levels of nuclear RBM3 ex-
pression. Based on their results, the authors postulated
that RBM3 expression may be used as a marker of disease
progression and that IHC assessment of RBM3 expression
could become a valuable tool to more accurately predict
aggressiveness of urothelial carcinoma. Although those re-
sults contradict the findings of the current study, several
differences that should be taken into account exist be-
tween the two studies. RBM3 nuclear score in Boman et
al. was trichotomized and dichotomized in various statis-
tical analyses while we evaluated H-score as a continuous
variable (Table 3). Also, and in comparison to our study
which only included cystectomy specimens with at least
muscle-invasive disease and only high-grade tumors,
Boman et al. samples originated from bladder biopsies or
transurethral resection specimens and included only non-
muscle-invasive tumors of any grade (24 % low grade).
Therefore, the concept of tumor progression and recur-
rence between the studies is set in two totally different clin-
ical contexts. Another different element between the two
studies are the pathological parameters that were correlated
along with RBM3 with outcome in statistical models; while
the current study included pT, pN, surgical margins status,
and lymphovascular invasion, Boman et al. included only
tumor grade and stage into account. Of note, the only two
studies on bladder carcinoma including the current one did
not use methods other than IHC to evaluate RBM3 expres-
sion. Additional studies using non-IHC techniques may be
needed to further elucidate the role of RBM3 and to
confirm its utility as a prognostic marker.
Conclusions
The current study shows that although stronger RBM3
immunoexpression correlates with metastases, RBM3
expression does not carry a prognostic significance with
respect to clinical outcome. This result contrasts with
the only other study published on RBM3 in urothelial
carcinoma so far, but the major study designs’ differ-
ences make further larger studies necessary before
reaching a definitive conclusion about the role of RBM3
in urothelial carcinoma. Importantly, the is a continuing
need to assess whether the RBM3 IHC results at differ-
ent stages of the disease only mark determining points
in the biological course of the disease or whether the
Table 3 Comparison of studied parameters between our study and the only other study on RBM3 in urothelial carcinoma
Current study Boman et al. [18]
Specimen type and tumor stagea Cystectomies Bladder biopsies
Transurethral resections of bladder tumors (TURBTs)
Distribution of high-grade disease 274/274 (100 %) 261/343 (76 %)
Categorization of patient groups Tumor stage
Lymph node involvement Tumor stage
Lymphovascular invasion Tumor grade
Surgical resection margin status
RBM3 IHC scoring H-score (continuous variable) Dichotomized and trichotomized nuclear scores
aPatients undergoing cystectomy for urothelial carcinoma have a worse prognosis due to muscle-invasive (higher stage) disease compared to patients who can initially
be managed medically (intravesicular bacillus Calmette-Guerin treatment) based on biopsy or TURBT results (non-muscle-invasive or lower stage disease)
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results indeed translate into true differences in the
clinical outcome for urothelial carcinoma patients.
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